CHRYSALIS is an ongoing study that is evaluating the effectiveness and safety of amivantamab-vmjw as monotherapy and in combination with other therapies in NSCLC and other solid malignancies harboring EGFR exon20ins mutations. Here, EGFR is linked to non-small cell lung carcinoma.